PeptideScanner retained ClinicalTrials.gov record NCT00663403 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-12-30, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02640976 at 2026-11-15T22:02:39.332Z. Its registry update date was 2015-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01917773 at 2026-07-30T21:39:57.679Z. Its registry update date was 2015-12-21, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02020629 at 2026-07-30T21:39:57.678Z. Its registry update date was 2015-12-15, and PeptideScanner's reviewed identity mapping was lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00076544 at 2026-07-30T21:39:57.683Z. Its registry update date was 2015-12-14, and PeptideScanner's reviewed identity mapping was ziconotide.
PeptideScanner retained ClinicalTrials.gov record NCT02622906 at 2026-11-15T22:05:38.400Z. Its registry update date was 2015-12-07, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT01155206 at 2026-07-30T21:39:57.683Z. Its registry update date was 2015-12-02, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01413542 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-11-04, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01160315 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-30, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT02102646 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-28, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01223937 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01262456 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00205426 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-10-14, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01753856 at 2026-07-30T21:39:57.682Z. Its registry update date was 2015-10-08, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01360424 at 2026-07-30T21:41:27.767Z. Its registry update date was 2015-09-29, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01785043 at 2026-07-30T21:41:27.766Z. Its registry update date was 2015-09-15, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01606072 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-08-28, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00005006 at 2026-07-30T21:41:27.764Z. Its registry update date was 2015-08-19, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00487188 at 2026-11-16T01:41:15.051Z. Its registry update date was 2015-08-13, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00473265 at 2026-07-30T21:41:27.762Z. Its registry update date was 2015-07-16, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01387347 at 2026-11-16T01:44:56.605Z. Its registry update date was 2015-07-10, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
PeptideScanner retained ClinicalTrials.gov record NCT00405548 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-07-01, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT01946568 at 2026-11-16T17:37:42.807Z. Its registry update date was 2015-06-23, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT01317004 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-06-22, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00986817 at 2026-11-15T21:47:40.408Z. Its registry update date was 2015-06-15, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00616460 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-06-12, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00947882 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-06-08, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01519518 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-05-13, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00780858 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-05-06, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00835848 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-05, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00527488 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-05-04, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00500110 at 2026-07-30T21:42:40.792Z. Its registry update date was 2015-04-28, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01473589 at 2026-07-30T21:42:40.788Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01473602 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01077323 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01297062 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02416271 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00375492 at 2026-07-30T21:42:40.801Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00500370 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00215683 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-04-01, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00004426 at 2026-07-30T21:43:54.469Z. Its registry update date was 2015-03-26, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00004436 at 2026-07-30T21:43:54.456Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00004438 at 2026-07-30T21:43:54.452Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01755572 at 2026-07-30T21:43:54.457Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01626560 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01682642 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT00772447 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-09, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT00381342 at 2026-07-30T21:43:54.470Z. Its registry update date was 2015-02-23, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00631527 at 2026-07-30T21:43:54.453Z. Its registry update date was 2015-01-29, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00748072 at 2026-11-15T22:08:31.832Z. Its registry update date was 2015-01-13, and PeptideScanner's reviewed identity mapping was vasopressin.